Coherus Oncology (CHRS) EBT Margin (2013 - 2026)

Coherus Oncology has disclosed EBT Margin across 13 years of filings, most recently posting 300.04% for Q1 2026.

• EBT Margin for Q1 2026 came in at 300.04%, up 32370.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 368.28% (up 25022.0% YoY), and the FY2025 annual result was 434.23%, up 38200.0% from the prior year.
• EBT Margin came in at 300.04% for Q1 2026 at Coherus Oncology, up from 363.56% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 53.67% in Q3 2023 to a low of 2947.83% in Q1 2024.
• The 5-year median for EBT Margin is 300.04% (2026), against an average of 469.63%.
• Across the five-year window, EBT Margin tumbled 271436 bps in 2024 and jumped 232409 bps in 2025, its largest moves.
• Coherus Oncology's EBT Margin stood at 129.81% in 2022, then soared by 33 bps to 87.03% in 2023, then tumbled by 585 bps to 596.06% in 2024, then soared by 39 bps to 363.56% in 2025, then grew by 17 bps to 300.04% in 2026.
• The last three EBT Margin figures came in at 300.04% (Q1 2026), 363.56% (Q4 2025), and 384.73% (Q3 2025), per Business Quant data.